Company Profile
Lineage Cell Therapeutics Stock Price, News & Analysis
- Ticker:
- LCTX
- Exchange:
- AMEX
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.13 USD (-0.88%)
Close
Last updated: August 6, 2026
302M USD
Market cap
Why the stock is moving
The latest monitored company update is “Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update.” The corresponding closing-price reaction is not yet available.
Company overview
Pluripotent Cell Therapy Company
Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform.
OpRegen
RG6501, formerly OpRegen, is a retinal pigment epithelium cell replacement therapy partnered with Roche and Genentech for geographic atrophy.
Wholly Owned Pipeline
Lineage is applying its platform to oligodendrocyte, auditory neuron, and corneal endothelial cell programs, including the newly launched COR1 program.
Manufacturing Model
The company differentiates and expands specific cell types from pluripotent master cell banks, supporting consistent and scalable production.
Future catalysts
Lineage Cell Therapeutics is heading into a more important stretch around its latest development priorities. Management's latest framing highlights Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Launched New Corneal Endothelial Disease Cell Therapy Program.... The stock is likely to react most to whether those milestones keep moving without a reset.
Recent news
- 01
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Source: Lineage Cell Therapeutics
- 02
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
Source: Lineage Cell Therapeutics
- 03
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
Source: Lineage Cell Therapeutics
- 04
Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
Source: Lineage Cell Therapeutics
- 05
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Source: Lineage Cell Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lineage Cell Therapeutics (LCTX)?
Lineage Cell Therapeutics (LCTX) most recently closed at 1.13 USD, a -0.88% move versus the previous session.
What is the market cap of Lineage Cell Therapeutics (LCTX)?
Lineage Cell Therapeutics currently has a market capitalization of 302M USD on BioPharmSignal.
What does Lineage Cell Therapeutics do?
Pluripotent Cell Therapy Company Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform. OpRegen RG6501, formerly OpRegen, is a retinal pigment epithelium cell replacement therapy partnered with Roche and Genentech for geographic atrophy. Wholly Owned...
On which exchange is LCTX stock listed?
Lineage Cell Therapeutics (LCTX) is associated with AMEX, United States, Biopharma.
What is Pluripotent?
Pluripotent Cell Therapy Company Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform.
Which conditions is Lineage Cell Therapeutics targeting with Pluripotent?
Pluripotent Cell Therapy Company Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform. OpRegen RG6501, formerly OpRegen, is a retinal pigment epithelium cell replacement therapy partnered with Roche and Genentech for geographic atrophy. Wholly Owned...
How does Lineage Cell Therapeutics describe recent progress with Pluripotent?
Lineage Cell Therapeutics is heading into a more important stretch around its latest development priorities. Management's latest framing highlights Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Launched New Corneal Endothelial Disease Cell Therapy Program.... The stock is likely to...
What is Cell?
Pluripotent Cell Therapy Company Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform.